GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$28.73
-0.07 (-0.24%)
▼
5d:
-1.54%
30d:
+13.83%
90d:
+1.88%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
21d
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GMAB shows positive signals but monitor for confirmation. Market pricing in 1.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GMAB shows positive signals but monitor for confirmation. Market pricing in 1.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.04
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$36.66
21.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $28.73, which is considered extended relative to its 30-day fair value range of $24.89 to $28.35. The stock's valuation (Forward PE: 15.8) is in line with its historical norms (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMAB is in a uptrend. Immediate support is located at $27.33, while resistance sits at $29.80.
Market Sentiment: GMAB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $36.74 (+27.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMAB is in a uptrend. Immediate support is located at $27.33, while resistance sits at $29.80.
Market Sentiment: GMAB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $36.74 (+27.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$24.89 -
$28.35
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.9% below Wall St target ($36.74)
Trading Range Analysis
30-Day Trading Range
$24.89 -
$28.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$27.33
Resistance Level
$29.80
Current Trend
Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.83
Wall Street Target
$36.74
(+27.9%)
Revenue Growth (YoY)
25.3%
Earnings Growth (YoY)
-72.8%
Profit Margin
21.1%
Valuation Discount vs History
-1.7% cheaper
PE vs Historical
15.8 vs 16.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.7%
(market-implied from PE analysis)
1-Year Target
$28.24
(-2%)
2-Year Target
$27.76
(-3%)
3-Year Target
$27.29
(-5%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$28.80
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 73.0%)
$133.45
(+365%)
Base:
(SPY PE: 15.8, Growth: 73.0%)
$96.96
(+238%)
Bear:
(PE: 13.5, Growth: 73.0%)
$82.42
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 21.98 | Current EPS (TTM): $1.31
Bull Case
$43.90
(+53%)
Analyst growth 38.6%, PE expands to 24.2
Base Case
$39.91
(+39%)
Market implied 38.6%, PE stable at 22.0
Bear Case
$19.58
(-32%)
Severe decline -20.0%, PE contracts to 18.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.8 to 16.7
Stabilization Target:
$30.32
(+5.5%)
PE Expansion Potential:
+5.5%
Share & Embed Analysis
Last updated: July 14, 2026 8:08 PM ET
Data refreshes hourly during market hours. Next update: 9:08 PM
Data refreshes hourly during market hours. Next update: 9:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
